Early versus delayed treatment of acute hepatitis C: Final results of the randomized controlled German HEP-NET acute HCV-III study
K Deterding, N Grüner, P Buggisch, J Wiegand, P Galle, U Spengler, H Hinrichsen, T Berg, A Potthoff, N Malek, H Diepolder, S Feyerabend, M Cornberg, MC Jung, MP Manns, H Wedemeyer · Zeitschrift für Gastroenterologie · 2012 · Heft 01
Bibliografische Angaben
Zusammenfassung
Early treatment of acute hepatitis C virus (HCV) infection with interferon alpha monotherapy is highly effective with SVR rates of >85%. An alternative strategy might be to delay treatment for 3 months and only to treat those patients who are not able to clear HCV spontaneously. The Hep-Net-Acute-HCV-III study was designed in 2004 as a prospective, randomized trial in patients with symptomatic acute hepatitis C comparing the efficacy and safety of immediate PEG-IFNa–2b treatment for 6 months (arm-A) versus delayed treatment with PEG-IFNa–2b plus ribavirin for 6 months starting 12 weeks after randomisation in pat…
